Copy to clipboard 
Orthopedic companies have generally gotten off to slower starts in 2025. Supply problems, market uncertainty and longer sales cycles are some of the obstacles companies have cited. We’ll update the orthopedic sales data below as companies report first quarter results.
About the Data
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for First Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,062.3 | $3,955.7 | $106.6 | 2.7% |
| Knees | $2,068.5 | $2,020.8 | $47.7 | 2.4% |
| Hips | $1,499.2 | $1,464.9 | $34.3 | 2.3% |
| Extremities | $494.6 | $470.0 | $24.6 | 5.2% |
| Spine | $1,159.4 | $1,137.8 | $21.6 | 1.9% |
| Trauma | $1,761.0 | $1,643.9 | $117.0 | 7.1% |
| Sports Medicine | $950.1 | $952.7 | ($2.6) | (0.3%) |
| Orthobiologics | $358.4 | $349.3 | $9.1 | 2.6% |
| Enabling Technology | $211.4 | $240.9 | ($29.5) | (12.2%) |
| Other | $644.4 | $651.0 | ($6.6) | (1%) |
| Total | $9,146.9 | $8,931.2 | $215.7 | 2.4% |
Total Orthopedic Sales for Reporting Companies
| Company | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| ATEC | $169.2 | $138.5 | $30.7 | 22.2% |
| Bioventus | $111.0 | $104.7 | $6.3 | 6% |
| CONMED | $138.3 | $134.9 | $3.4 | 2.5% |
| Globus Medical | $598.1 | $606.7 | ($8.5) | (1.4%) |
| J&J MedTech | $2,241.2 | $2,340.4 | ($99.3) | (4.2%) |
| Orthofix Medical | $193.6 | $188.6 | $5.0 | 2.7% |
| SI-BONE | $47.3 | $37.9 | $9.4 | 24.9% |
| Smith+Nephew | $971.4 | $960.3 | $11.1 | 1.2% |
| Stryker | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
| Zimmer Biomet | $1,909.1 | $1,889.2 | $20.0 | 1.1% |
| Total | $9,146.9 | $8,931.2 | $215.7 | 2.4% |
Orthopedic Market Developments for First Quarter 2025
J&J MedTech Contends With Multiple One-Time Items
Three one-time items impacted orthopedic results in the first quarter: a revenue recognition timing change, fewer selling days and impacts from orthopedic restructuring that the company initiated in 2023. Accounting for those changes, operational growth for J&J MedTech’s worldwide orthopedics was closer to 2% growth.
CONMED Focused on Supply Chain Improvement
The company’s supply chain improvement initiative has three focus areas: procurement and relationships with supply partners, better production planning and production itself. CONMED said it made early progress in the first quarter, reducing the number of SKUs on backorder, but isn’t where it needs to be.
Smith+Nephew Incurs Significant VBP Headwinds
The company’s sports medicine business was impacted by the implementation of volume-based procurement in China, equating to a 7.7% headwind on joint repair products and 3.4% headwind on arthroscopic enabling technology.
Stryker Notches Record First Quarter for Mako Installs
Stryker said the first quarter of 2025 was its largest ever for Mako installations. The company’s spine robot is set for full commercial launch in the second half of this year, with Mako Shoulder hitting the market in the first quarter of 2026.
Zimmer Biomet to Make Changes to U.S. Sales Channel
The company is making changes in leadership, territory alignment and incentive plans. Zimmer Biomet plans to invest more in its SET category, robotics and the ASC environment.
Globus Medical Turns in Rare Soft Quarter
The company experiences softer enabling technology sales based on difficult comps against a record first quarter last year, as well as elongated selling cycles due to market uncertainty.
Orthopedic companies have generally gotten off to slower starts in 2025. Supply problems, market uncertainty and longer sales cycles are some of the obstacles companies have cited. We'll update the orthopedic sales data below as companies report first quarter results.
About the Data
The data below is based on reported sales from a subset of...
Orthopedic companies have generally gotten off to slower starts in 2025. Supply problems, market uncertainty and longer sales cycles are some of the obstacles companies have cited. We’ll update the orthopedic sales data below as companies report first quarter results.
About the Data
The data below is based on reported sales from a subset of public orthopedic companies on a quarterly reporting schedule. These companies account for about two-thirds of the global market. I’m using this group as a proxy to measure quarterly market performance.
Orthopedic Market Data for First Quarter 2025
Where applicable, company names for the current quarter are linked to a more detailed article containing highlights and segment and regional sales data.
Sales for consolidated half, nine months and full-year results are inclusive of all previously-reported data plus data from companies that have reported in the current quarter.
Segment Sales for Reporting Companies
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $4,062.3 | $3,955.7 | $106.6 | 2.7% |
| Knees | $2,068.5 | $2,020.8 | $47.7 | 2.4% |
| Hips | $1,499.2 | $1,464.9 | $34.3 | 2.3% |
| Extremities | $494.6 | $470.0 | $24.6 | 5.2% |
| Spine | $1,159.4 | $1,137.8 | $21.6 | 1.9% |
| Trauma | $1,761.0 | $1,643.9 | $117.0 | 7.1% |
| Sports Medicine | $950.1 | $952.7 | ($2.6) | (0.3%) |
| Orthobiologics | $358.4 | $349.3 | $9.1 | 2.6% |
| Enabling Technology | $211.4 | $240.9 | ($29.5) | (12.2%) |
| Other | $644.4 | $651.0 | ($6.6) | (1%) |
| Total | $9,146.9 | $8,931.2 | $215.7 | 2.4% |
Total Orthopedic Sales for Reporting Companies
| Company | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| ATEC | $169.2 | $138.5 | $30.7 | 22.2% |
| Bioventus | $111.0 | $104.7 | $6.3 | 6% |
| CONMED | $138.3 | $134.9 | $3.4 | 2.5% |
| Globus Medical | $598.1 | $606.7 | ($8.5) | (1.4%) |
| J&J MedTech | $2,241.2 | $2,340.4 | ($99.3) | (4.2%) |
| Orthofix Medical | $193.6 | $188.6 | $5.0 | 2.7% |
| SI-BONE | $47.3 | $37.9 | $9.4 | 24.9% |
| Smith+Nephew | $971.4 | $960.3 | $11.1 | 1.2% |
| Stryker | $2,767.7 | $2,530.2 | $237.5 | 9.4% |
| Zimmer Biomet | $1,909.1 | $1,889.2 | $20.0 | 1.1% |
| Total | $9,146.9 | $8,931.2 | $215.7 | 2.4% |
Orthopedic Market Developments for First Quarter 2025
J&J MedTech Contends With Multiple One-Time Items
Three one-time items impacted orthopedic results in the first quarter: a revenue recognition timing change, fewer selling days and impacts from orthopedic restructuring that the company initiated in 2023. Accounting for those changes, operational growth for J&J MedTech’s worldwide orthopedics was closer to 2% growth.
CONMED Focused on Supply Chain Improvement
The company’s supply chain improvement initiative has three focus areas: procurement and relationships with supply partners, better production planning and production itself. CONMED said it made early progress in the first quarter, reducing the number of SKUs on backorder, but isn’t where it needs to be.
Smith+Nephew Incurs Significant VBP Headwinds
The company’s sports medicine business was impacted by the implementation of volume-based procurement in China, equating to a 7.7% headwind on joint repair products and 3.4% headwind on arthroscopic enabling technology.
Stryker Notches Record First Quarter for Mako Installs
Stryker said the first quarter of 2025 was its largest ever for Mako installations. The company’s spine robot is set for full commercial launch in the second half of this year, with Mako Shoulder hitting the market in the first quarter of 2026.
Zimmer Biomet to Make Changes to U.S. Sales Channel
The company is making changes in leadership, territory alignment and incentive plans. Zimmer Biomet plans to invest more in its SET category, robotics and the ASC environment.
Globus Medical Turns in Rare Soft Quarter
The company experiences softer enabling technology sales based on difficult comps against a record first quarter last year, as well as elongated selling cycles due to market uncertainty.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
